Current Grants

Since the beginning, the primary goal of The Alternating Hemiplegia of Childhood Foundation is to raise funds for research and to find a cure and treatment(s) for all children with AHC. We are currently funding the following grants related to this goal. For the full text of the grants, please email sharon@ahckids.org

AHCF funds next phase of Vanderbilt Grant

2014 Molecular Physiology and Pharmacology of ATP1A3 Mutations in AHC

Christine Simmons lab#2The Alternating Hemiplegia of Childhood Foundation is pleased to announce that we have partially funded phase three of a research grant awarded to Dr. Kevin Ess at Vanderbilt University and Dr. Alfred George, Jr. at Northwestern University in the amount of $140,807.00.  
(more…)

Research Grant awarded to Radboud University Nijmegen the Netherlands

$13,500.00  was awarded to Dr. Jan B Koenderink, Radboud University Nijmegen Medical Centre, The Netherlands. His group will study the molecular consequences of at least six different ATP1A3 mutations in functional in vitro assays. Eventually, the relationship between these mutations and AHC will be evaluated.

This grant was a collaborative effort between the AHCF and the AHC Association of Iceland. http://ahckids.org/ahcf-ahc-is-fund-research-grant/

Research Grant awarded to Vanderbilt University

2013 Molecular Physiology and Pharmacology of ATP1A3 Mutations in AHC

$169,154 grant awarded to Dr. Alfred George, Jr. and Dr. Kevin Ess at Vanderbilt University to determine the functional and biochemical consequences of the three most common gene mutations causing AHC, to identify drugs or drug-like compounds capable of restoring normal gene function, and to investigate the electrophysiological properties of human neurons generated from induced pluripotent stem cells derived from AHC patients.

Quote from Dr. George:

‘We are honored to work with the Foundation and its membership to help understand the basis for AHC and to seek new treatment strategies. This very generous donation will enable us to determine how ATP1A3 mutations cause AHC and to find pharmacological strategies to correct the defect. While animal research is always very important, this work will use human neurons generated from patients with AHC.